12:00 AM
 | 
Mar 16, 2009
 |  BC Week In Review  |  Company News  |  Deals

Genavia Therapeutics Ltd., Origen Therapeutics Inc., Symphogen deal

The partners will develop transgenic chickens which produce human antibodies for cancer and infectious and autoimmune diseases. Origen will provide its avian transgenic technology, and Symphogen will use its Symplex technology to create recombinant...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >